Top Markets
#1 Akedo Akedo +73.50%
#2 MEET48 MEET48 +26.11%
#3 Bitway Bitway +21.76%
#4 VeThor VeThor +21.08%
#5 Power Protocol Power Protocol +17.38%
#6 Tutorial Tutorial +16.23%
#7 Astar Astar +14.86%
#8 龙虾 (Lobster) 龙虾 (Lobster) +12.72%
#9 Falcon Finance Falcon Finance +12.11%
#10 Arbitrum Arbitrum +12.09%
Coin of the day
Akedo Akedo
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Classement en actions #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Prix de l'action
$0.25974701
Dernière synchronisation: 2025-01-06
Capitalisation boursière
$2.04M
Changement (1 jour)
0.74%
Changement (1 an)
0.00%
Pays
FR
Échange Acticor Biotech SAS (ALACT)

Catégorie

Healthcare
Ratio P/B pour Acticor Biotech SAS (ALACT)
Ratio P/B au September 2026 TTM : -0.57
Selon les derniers rapports financiers et le cours de l'action de Acticor Biotech SAS, le ratio cours/valeur comptable actuel (TTM) est -0.57. À la fin de 2022, le ratio P/B était de -33.19.
Historique du ratio P/B pour Acticor Biotech SAS de 2010 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
2026 (TTM) -0.57 -91.38%
2023 -6.59 -80.15%
2022 -33.19 -1,126.36%
2021 3.23 -87.62%
2020 26.12 538.96%
2019 4.09 17.85%
2018 3.47 -160.01%
2017 -5.78 -511.84%
2016 1.40 2.83%
2015 1.37 7.92%
2014 1.26 5.23%
2013 1.20 -8.34%
2012 1.31 -12.44%
2011 1.50 -91.22%
2010 17.05 0.00%
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.5144 -1,247.10%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.3983 -1,402.75%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 3.9974 -803.89%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 8.5918 -1,612.91%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH